Loading clinical trials...

Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C

A Phase 3 Study of MP-424 in Combination With Peginterferon Alfa-2b and Ribavirin, in Treatment-Naïve Subjects With Genotype 1 Hepatitis C

NCT00780416•Tanabe Pharma Corporation

View on ClinicalTrials.gov

Summary

This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b (PEG-IFN) and Ribavirin (RBV) in treatment-naïve patients with (Genotype 1) hepatitis C.

Eligibility

Age

20 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Genotype 1, chronic hepatitis C
•Treatment-naïve (patient who has received no previous interferon based treatment for hepatitis C)
•Able and willing to follow contraception requirements

Exclusion Criteria

•Cirrhosis of the liver or hepatic failure
•Hepatitis B surface antigen-positive or HIV antibodies-positive
•History of, or concurrent hepatocellular carcinoma
•History of, or concurrent depression, schizophrenia; or suicide attempt in the past
•Pregnant, lactating, or suspected pregnant patients, or male patients whose female partner is pregnant

Locations (1)

Toranomon Hospital

Kawasaki, Takatsu-ku, Japan

Key Dates

Start Date

November 1, 2008

Primary Completion Date

August 1, 2010

Completion Date

August 1, 2010

Last Updated

January 6, 2026

Enrollment

189

ACTUAL participants

Conditions

Hepatitis C

Interventions

MP-424

DRUG

Ribavirin

DRUG

Peginterferon Alfa-2b

DRUG

Ribavirin

DRUG

Peginterferon Alfa-2b

DRUG

Implementing Low-Barrier HCV Treatment in a Jail Setting

NCT06953479

HEPATITIS C (HCV)Incarceration+2 more

View study

RECRUITINGNA

Project I Test: Implementing HIV Testing in Opioid Treatment Programs

NCT03135886

HIV/AIDSHepatitis C+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 6, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C

Inclusion Criteria

Exclusion Criteria

Implementing Low-Barrier HCV Treatment in a Jail Setting

Project I Test: Implementing HIV Testing in Opioid Treatment Programs

Persuasive Health Communication Intervention for HIV/HCV

The National Australian HCV Point-of-Care Testing Program

Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)

Acceptability of Simultaneous Screening for Viral Hepatitis B, C and HIV Among Drug Users in Non-conventional Structures